AR049488A1 - Complejos de inclusiones obtenidos al utilizar un procedimiento con co2 supercritico y un agente de interaccion con el complejo - Google Patents

Complejos de inclusiones obtenidos al utilizar un procedimiento con co2 supercritico y un agente de interaccion con el complejo

Info

Publication number
AR049488A1
AR049488A1 ARP050101306A ARP050101306A AR049488A1 AR 049488 A1 AR049488 A1 AR 049488A1 AR P050101306 A ARP050101306 A AR P050101306A AR P050101306 A ARP050101306 A AR P050101306A AR 049488 A1 AR049488 A1 AR 049488A1
Authority
AR
Argentina
Prior art keywords
complex
supercritical
complexes
interaction
procedure
Prior art date
Application number
ARP050101306A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0403450A external-priority patent/FR2868315B1/fr
Priority claimed from FR0411201A external-priority patent/FR2876911B1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR049488A1 publication Critical patent/AR049488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente se refiere a un procedimiento de preparacion de un compuesto de inclusion soluble que comprende una o varias sustancias activas poco solubles en un medio acuoso incluídas en una o varias moléculas huéspedes, caracterizado por comprender las etapas sucesivas siguientes: a) puesta en contacto de una o varias sustancias activas con una o varias moléculas huéspedes; b) implementacion de una etapa de difusion molecular por puesta en contacto, en modo estático, de un fluído denso bajo presion con la mezcla obtenida en la etapa a) en presencia de uno o varios agentes de difusion; c) recuperacion del complejo de inclusion soluble formado de esta manera. Se refiere igualmente al compuesto de inclusion soluble susceptible de obtenerse por medio de este procedimiento, en particular un complejo piroxicam-ciclodextrina-arginina.
ARP050101306A 2004-04-01 2005-04-01 Complejos de inclusiones obtenidos al utilizar un procedimiento con co2 supercritico y un agente de interaccion con el complejo AR049488A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403450A FR2868315B1 (fr) 2004-04-01 2004-04-01 Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
FR0411201A FR2876911B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine

Publications (1)

Publication Number Publication Date
AR049488A1 true AR049488A1 (es) 2006-08-09

Family

ID=34968371

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101306A AR049488A1 (es) 2004-04-01 2005-04-01 Complejos de inclusiones obtenidos al utilizar un procedimiento con co2 supercritico y un agente de interaccion con el complejo

Country Status (16)

Country Link
US (2) US8461133B2 (es)
EP (2) EP1729813B1 (es)
JP (1) JP5091661B2 (es)
AR (1) AR049488A1 (es)
AT (1) ATE504316T1 (es)
BR (1) BRPI0509482B1 (es)
CA (1) CA2563101C (es)
CY (1) CY1114198T1 (es)
DE (1) DE602005027333D1 (es)
DK (1) DK2260871T3 (es)
ES (1) ES2424235T3 (es)
PL (2) PL1729813T3 (es)
PT (2) PT1729813E (es)
RU (1) RU2382654C2 (es)
SI (1) SI2260871T1 (es)
WO (1) WO2005097201A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
FR2876914A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
KR101383941B1 (ko) 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
WO2018035459A1 (en) * 2016-08-19 2018-02-22 Chen, Zunxuan Pharmaceutical composition and methods of uses
CN109142420B (zh) * 2018-10-12 2020-01-10 厦门大学 基于核磁共振技术探究药物在胶束内最大增溶量的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434163A (en) 1981-06-01 1984-02-28 Pfizer Inc. Water-soluble benzothiazine dioxide salts
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPS632929A (ja) * 1986-06-20 1988-01-07 Kao Corp アセチルサリチル酸製剤
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
IT1241088B (it) 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
ATE144680T1 (de) * 1990-08-13 1996-11-15 Commw Scient Ind Res Org Pestizide produkte
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
AT400674B (de) 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
IT1293764B1 (it) 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
PT1018340E (pt) 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830761B1 (fr) 2001-10-12 2003-12-12 Pf Medicament Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
FR2830760B1 (fr) 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
ATE486587T1 (de) * 2002-01-15 2010-11-15 Ucb Farchim Sa Formulierungen zur oralen verabreichung von wirkstoffen
ATE359827T1 (de) * 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
WO2005112637A1 (en) 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins

Also Published As

Publication number Publication date
PT1729813E (pt) 2011-07-12
RU2382654C2 (ru) 2010-02-27
US8461133B2 (en) 2013-06-11
CA2563101A1 (fr) 2005-10-20
JP5091661B2 (ja) 2012-12-05
US20070270379A1 (en) 2007-11-22
CY1114198T1 (el) 2016-08-31
BRPI0509482A (pt) 2007-09-11
US9243076B2 (en) 2016-01-26
DK2260871T3 (da) 2013-08-26
EP2260871A2 (fr) 2010-12-15
DE602005027333D1 (de) 2011-05-19
WO2005097201A2 (fr) 2005-10-20
JP2007530641A (ja) 2007-11-01
RU2006138488A (ru) 2008-05-10
WO2005097201A3 (fr) 2006-08-17
PL1729813T3 (pl) 2011-09-30
US20130316975A1 (en) 2013-11-28
CA2563101C (fr) 2013-07-02
ES2424235T3 (es) 2013-09-30
EP1729813B1 (fr) 2011-04-06
BRPI0509482B1 (pt) 2018-12-11
PL2260871T3 (pl) 2013-10-31
EP1729813A2 (fr) 2006-12-13
SI2260871T1 (sl) 2013-09-30
ATE504316T1 (de) 2011-04-15
EP2260871B1 (fr) 2013-05-15
EP2260871A3 (fr) 2011-05-18
PT2260871E (pt) 2013-08-01

Similar Documents

Publication Publication Date Title
AR049488A1 (es) Complejos de inclusiones obtenidos al utilizar un procedimiento con co2 supercritico y un agente de interaccion con el complejo
HK1082430A1 (en) Method for the preparation of molecular complexes
DE602006015292D1 (de) Zuführung von molekülen an eine lipiddoppelschicht
AU2002212412A1 (en) Method for making very fine particles consisting of a principle inserted in a host molecule
AR060894A1 (es) Aparato basado en membrana y metodo asociado
AR066427A1 (es) Metodo para limpiar membranas contaminadas y o escamadas
TW200712114A (en) Method for manufacturing particulate water-absorbing agent and particulate water-absorbing agent
SG169968A1 (en) Adhesive composition for use in an immunosensor
EA201270354A1 (ru) Полимерные добавки для расширения технических возможностей технологических жидкостей, содержащих вязкоупругие пав, и способы их применения
AR063587A1 (es) Preparcion liquida que comprende pimobendan
WO2007076392A3 (en) A method for reusing rhenium from a donor spent epoxidation catalyst
AR051455A1 (es) Sistema y metodo de esterilizacion y aparato de control de entrada de orificio para la misma
WO2007093981A3 (en) Systems and methods for sensing analyte and dispensing therapeutic fluid
EA201070008A1 (ru) Композиции для уплотнения частиц в скважинах подземного угольного пласта
ECSP099594A (es) Tratamientos de bananos
AR032386A1 (es) Preparaciones de ciclodextrina
WO2012079030A3 (en) Bioconjugation using bifunctional linkers
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
BR0213220A (pt) Processo de preparação de compostos de interação de uma substância ativa pouco solúvel em um meio aquoso com um suporte poroso, e, composto de interação de interação de uma substância ativa pouco solúvel em um meio aquoso em um suporte aquoso
EA200901353A1 (ru) Композиции углеводородных жидкостей и способы их применения
ITMI20111650A1 (it) Complesso bis-imminico di lantanidi, sistema catalitico comprendente detto complesso bis-imminico e procedimento per la (co)polimerizzazione di dieni coniugati
EP2057899A3 (en) Method for making cyclopropene inclusion complex
DE602005010400D1 (de) Verfahren zur funktionalisierung von konjugierten oder konjugierbaren derivaten unter zuhilfenahme eines elektrophoren mediators vom tempo-typ
ITMI20111651A1 (it) Complesso bis-immino piridinico di lantanidi, sistema catalitico comprendente detto complesso bis-immino piridinico e procedimento per la (co)polimerizzazione di dieni coniugati
ATE368451T1 (de) Verfahren zum überziehen von feststoffteilchen

Legal Events

Date Code Title Description
FB Suspension of granting procedure